MDCX vs NSRX

Medicus Pharma Ltd. vs Nasus Pharma Ltd. — Valuation Comparison 2026

MDCX

Drug Manufacturers - General
Medicus Pharma Ltd.
Quality
3.2
out of 10
Value Trap
12
SAFE
Price
$0.33
Last close
Models
7/13
Active
VS

NSRX

Drug Manufacturers - General
Nasus Pharma Ltd.
Quality
1.9
out of 10
Value Trap
Price
$3.20
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType MDCX Fair ValueMDCX Upside NSRX Fair ValueNSRX Upside
Bayesian DCF Intrinsic $0.13 -61.7% $0.85 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.21 -34.9% $0.15 -94.9%
PWERM Option-Based $0.38 +14.9% $2.27 -24.8%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MDCX vs NSRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MDCX vs NSRX — Which Stock Is More Undervalued?

MDCX scores higher with a 3.2/10 quality rating vs NSRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Medicus Pharma Ltd. (MDCX) and Nasus Pharma Ltd. (NSRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MDCX currently trades at $0.33 with a QOC of 3.2/10, while NSRX trades at $3.20 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).